Neurocrine price target raised to $195 from $183 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm's price target on Neurocrine to $195 from $183 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June rel